FDA Adverse Event Injury Summary report: N

TAXUS ELEMENT PACLITAXEL-ELUTING CORONARY STENT SYSTEM

MDR report key: 2221051 · Received August 23, 2011

Report

Report Number
2134265-2011-03645
Event Type
Injury
Date Received
August 23, 2011
Date of Event
June 16, 2011
Report Date
July 27, 2011
Manufacturer
BOSTON SCIENTIFIC - GALWAY
Product Code
NIQ
PMA / PMN Number
P100023
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GB
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

DEVICE IS A COMBINATION PRODUCT. DEVICE EVALUATED BY MFR: IT IS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION; THEREFORE A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. A REVIEW OF THE BATCH HISTORY, HISTORICAL TRENDING, AND SIMILAR COMPLAINT TRENDING REVIEW FOR THE PRODUCT FAMILY WILL BE CONDUCTED. IF THERE IS ANY FURTHER RELEVANT INFORMATION FROM THAT REVIEW, A SUPPLEMENTAL MEDWATCH WILL BE FILED. (B)(4).

Description of Event or Problem · 1

SAME CASE AS MFR REPORT #: 2134265-2011-03644. (B)(6) TRIAL. IT WAS REPORTED THAT FOLLOWING A CORONARY ARTERY STENTING TREATMENT PROCEDURE THE PATIENT EXPERIENCED CHEST PAIN. THE INDEX PROCEDURE TREATED THE PROXIMAL CIRCUMFLEX AND MID LEFT ANTERIOR DESCENDING (LAD) WITH TWO TAXUS ELEMENT STENTS RESULTING IN 0% RESIDUAL STENOSIS. THE PATIENT WAS DISCHARGED THE SAME DAY ON ASPIRING AND CLOPIDOGREL. IN (B)(6) 2011, THE PATIENT RETURNED WITH CHEST PAIN FOR AN ELECTIVE ANGIOGRAM. ANGIOGRAPHY SHOWED MILD CORONARY ARTERY DISEASE AT THE TWO EXISTING STENTS IN THE PROXIMAL TO MID LAD AND OSTIAL CIRCUMFLEX. AN EXERCISE TOLERANCE TEST WAS NEGATIVE FOR ISCHEMIA, BUT THE PATIENT WAS SYMPTOMATICALLY POSITIVE. THERE WERE NO ELEVATED CARDIAC MARKERS. THE PATIENT WAS TO BE MEDICALLY MANAGED WITH AN INCREASED DOSAGE OF ISMN.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TAXUS ELEMENT PACLITAXEL-ELUTING CORONARY STENT SYSTEM CORONARY DRUG-ELUTING STENT NIQ BOSTON SCIENTIFIC - GALWAY H7493902512300 13911116

Patients

Seq Age Sex Outcome Treatment
1 60 YR Required Intervention